摘要
目的新生儿呼吸窘迫综合征(NRDS)使用NCPAP及常规处理后,治疗组加用珂立苏,比较分析2组的疗效。方法对照组28例采用NCPAP及常规治疗,治疗组24例加用珂立苏,观察治疗前后2组患儿血气、X线胸片及并发症情况。结果用药后24h,2组患儿血气改变明显不同,差异有统计学意义(P<0.05)。治疗组肺炎发生率显著低于对照组(P<0.01),吸氧时间明显较对照组低,差异有统计学意义(P<0.05)。结论国产肺泡表面活性物质珂立苏联合新型鼻塞持续气道正压通气治疗NRDS疗效满意。
Objective Neonates with respiratory distress syndrome were treated by NCPAP and routine treatment,observed group was treated with calf pulmonary surfactant for Injection,we compared the observed group and control group.Methods The observed group was treated with NCPAP and pulmonary surfactant for Injection treatment group,we observed the changes of blood gases,chest X-ray,clinical effects and secondary outcome before and after treatment.Results PS PaO2 and PaO2 /Fio2 of the NRDS infants in two groups 24 hours after the administration increased rapidly.There was significant difference compared with those before the treatment(P<0.01).There was no significant difference between the two groups in blood gas(P>0.05).The duration of supplemental oxygen was significantly shorter in the observed group.(P<0.05).Pneumonia occurred rate was significantly declined(P<0.05).Conclusion Calf pulmonary surfactant for Injection and(NCPAP)is a safe and effective primary remedly to newborn infants with RDS.
出处
《基层医学论坛》
2008年第S1期4-6,共3页
The Medical Forum
